Cargando…
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618297/ https://www.ncbi.nlm.nih.gov/pubmed/23497499 http://dx.doi.org/10.1186/1756-9966-32-12 |